These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
212 related articles for article (PubMed ID: 33438540)
1. Optimization of Performance Variables of Exemestane Nanosuspension Using Box-Behnken Design to Improve Dissolution and Oral Bioavailability. Parmar K; Shah J Curr Drug Deliv; 2021; 18(8):1148-1161. PubMed ID: 33438540 [TBL] [Abstract][Full Text] [Related]
2. Increase in Dissolution Rate of Zotepine via Nanomilling Process - Impact of Dried Nanocrystalline Suspensions on Bioavailability. Parmar K; Oza K AAPS PharmSciTech; 2021 Dec; 23(1):20. PubMed ID: 34907489 [TBL] [Abstract][Full Text] [Related]
3. A quality-by-design study to develop Nifedipine nanosuspension: examining the relative impact of formulation variables, wet media milling process parameters and excipient variability on drug product quality attributes. Patel PJ; Gajera BY; Dave RH Drug Dev Ind Pharm; 2018 Dec; 44(12):1942-1952. PubMed ID: 30027778 [TBL] [Abstract][Full Text] [Related]
4. Development of olmesartan medoxomil optimized nanosuspension using the Box-Behnken design to improve oral bioavailability. Nagaraj K; Narendar D; Kishan V Drug Dev Ind Pharm; 2017 Jul; 43(7):1186-1196. PubMed ID: 28271908 [TBL] [Abstract][Full Text] [Related]
5. Development of an amorphous nanosuspension by sonoprecipitation-formulation and process optimization using design of experiment methodology. Gajera BY; Shah DA; Dave RH Int J Pharm; 2019 Mar; 559():348-359. PubMed ID: 30721724 [TBL] [Abstract][Full Text] [Related]
6. Enhanced Solubility and Dissolution Rate of Lacidipine Nanosuspension: Formulation Via Antisolvent Sonoprecipitation Technique and Optimization Using Box-Behnken Design. Kassem MAA; ElMeshad AN; Fares AR AAPS PharmSciTech; 2017 May; 18(4):983-996. PubMed ID: 27506564 [TBL] [Abstract][Full Text] [Related]
7. Preparation and Characterization of Stable Nanosuspension for Dissolution Rate Enhancement of Furosemide: A Quality by Design (QbD) Approach. Marzan AL; Tabassum R; Jahan B; Asif MH; Reza HM; Kazi M; Alshehri SM; de Matas M; Shariare MH Curr Drug Deliv; 2018; 15(5):672-685. PubMed ID: 29359667 [TBL] [Abstract][Full Text] [Related]
8. Improved oral bioavailability for lutein by nanocrystal technology: formulation development, in vitro and in vivo evaluation. Chang D; Ma Y; Cao G; Wang J; Zhang X; Feng J; Wang W Artif Cells Nanomed Biotechnol; 2018 Aug; 46(5):1018-1024. PubMed ID: 28749189 [TBL] [Abstract][Full Text] [Related]
9. Fabrication of Ibrutinib Nanosuspension by Quality by Design Approach: Intended for Enhanced Oral Bioavailability and Diminished Fast Fed Variability. Rangaraj N; Pailla SR; Chowta P; Sampathi S AAPS PharmSciTech; 2019 Oct; 20(8):326. PubMed ID: 31659558 [TBL] [Abstract][Full Text] [Related]
10. Formulation, optimization and in vitro-in vivo evaluation of febuxostat nanosuspension. Ahuja BK; Jena SK; Paidi SK; Bagri S; Suresh S Int J Pharm; 2015 Jan; 478(2):540-52. PubMed ID: 25490182 [TBL] [Abstract][Full Text] [Related]
11. Formulation and Characterization of Ursodeoxycholic Acid Nanosuspension Based on Bottom-Up Technology and Box-Behnken Design Optimization. Boscolo O; Flor S; Salvo L; Dobrecky C; Höcht C; Tripodi V; Moretton M; Lucangioli S Pharmaceutics; 2023 Jul; 15(8):. PubMed ID: 37631251 [TBL] [Abstract][Full Text] [Related]
12. The Impact of Process and Formulation Parameters on the Fabrication of Efavirenz Nanosuspension to Improve Drug Solubility and Dissolution. Rashed M; Dadashzadeh S; Bolourchian N Iran J Pharm Res; 2022 Dec; 21(1):e129409. PubMed ID: 36942076 [TBL] [Abstract][Full Text] [Related]
13. Etoposide Amorphous Nanopowder for Improved Oral Bioavailability: Formulation Development, Optimization, in vitro and in vivo Evaluation. Wang Y; Wang S; Xu Y; Wang P; Li S; Liu L; Liu M; Jin X Int J Nanomedicine; 2020; 15():7601-7613. PubMed ID: 33116490 [TBL] [Abstract][Full Text] [Related]
14. Cefdinir nanosuspension for improved oral bioavailability by media milling technique: formulation, characterization and in vitro-in vivo evaluations. Sawant KK; Patel MH; Patel K Drug Dev Ind Pharm; 2016; 42(5):758-68. PubMed ID: 26548349 [TBL] [Abstract][Full Text] [Related]
15. A new nanosuspension prepared with wet milling method for oral delivery of highly variable drug Cyclosporine A: development, optimization and in vivo evaluation. Pınar SG; Canpınar H; Tan Ç; Çelebi N Eur J Pharm Sci; 2022 Apr; 171():106123. PubMed ID: 35017012 [TBL] [Abstract][Full Text] [Related]
16. Shariare MH; Altamimi MA; Marzan AL; Tabassum R; Jahan B; Reza HM; Rahman M; Ahsan GU; Kazi M Saudi Pharm J; 2019 Jan; 27(1):96-105. PubMed ID: 30662312 [TBL] [Abstract][Full Text] [Related]
17. Surface Engineering of Fenofibrate Nanocrystals Using Nano-by-Design Multivariate Integration: A Biopharmaceutical and Pharmacokinetic Perspective. Gite S; Kakade P; Patravale V Curr Drug Deliv; 2021; 18(9):1314-1329. PubMed ID: 33655832 [TBL] [Abstract][Full Text] [Related]
18. Preparation, Characterization and In Vivo Assessment of Repaglinide Nanosuspension for Oral Bioavailability Improvement. Zawar LR; Bari SB Recent Pat Drug Deliv Formul; 2018; 12(3):162-169. PubMed ID: 30003863 [TBL] [Abstract][Full Text] [Related]
19. Formulation of Aceclofenac Tablets Using Nanosuspension as Granulating Agent: An Attempt to Enhance Dissolution Rate and Oral Bioavailability. Rahim H; Sadiq A; Ullah R; Bari A; Amin F; Farooq U; Ullah Jan N; Mahmood HM Int J Nanomedicine; 2020; 15():8999-9009. PubMed ID: 33235448 [TBL] [Abstract][Full Text] [Related]
20. Enhanced biopharmaceutical performance of brick dust molecule nilotinib via stabilized amorphous nanosuspension using a facile acid-base neutralization approach. Chougule M; Sirvi A; Saini V; Kashyap M; Sangamwar AT Drug Deliv Transl Res; 2023 Oct; 13(10):2503-2519. PubMed ID: 37024611 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]